A common but poorly mapped experience
As psychedelic substances are studied as possible treatments for mental health conditions, clinicians are also working to understand effects that can persist after the immediate drug experience has ended. A new study from researchers at Yale School of Medicine examines those lingering visual effects, which the researchers call persisting perceptual abnormalities, or PPAs, and asks whether they resemble hallucination-related experiences used in psychosis-risk assessment.
The question matters because a person can report an unusual perceptual experience without having psychosis. In the account that opens the research discussion, a 25-year-old man described repeatedly seeing a large, unblinking eye on his ceiling as he fell asleep. He was not taking drugs at the time and did not have psychosis, but he had previously used psychedelics and worried that the experience meant he was developing the condition.
According to Max Greenwald, an M.D.-Ph.D. student at Yale School of Medicine and a study author, it remains unclear whether such an experience indicates a greater risk of psychosis. Yet it could raise a person’s score on a scale clinicians use to identify people at elevated risk. That uncertainty is central to the work, published in Scientific Reports by Greenwald and Albert Powers, medical director of Yale’s PRIME Psychosis Risk Clinic.
What the researchers measured
The study focused on people who had used psychedelics and on visual effects that began afterward. Researchers recruited 186 psychedelic users, largely through online forums. More than half said they had experienced PPAs after psychedelic use.
The reported frequency should not be interpreted as a rate of a disorder, the researchers emphasized through the study’s design. Visual changes after psychedelic use have long been recognized under the label hallucinogen persisting perception disorder, or HPPD. That diagnosis requires clinically meaningful distress and impairment. The Yale study deliberately did not require distress in order to examine a broader range of perceptual changes.
That distinction produced an important result: more than 90% of participants reported no distress from their experiences. The most common reported effect was brighter colors, an experience that is not necessarily disruptive. In other words, a lingering change in perception may be noticeable without being a clinical problem.
Why the overlap deserves attention
Psychedelic experiences are suspected to involve changes in how the brain receives, interprets and organizes information. The new work examines whether some persisting effects may function like the hallucination-related experiences considered in psychosis assessment. It does not establish that psychedelic aftereffects cause psychosis, nor does it establish that every unusual visual experience after psychedelic use is harmless.
Instead, the study highlights a practical screening problem. If questionnaires identify perceptual abnormalities but do not distinguish their timing, context, distress level and functional impact, clinicians may have difficulty separating benign or non-distressing aftereffects from signs that warrant closer evaluation. The ceiling-eye account illustrates why a single symptom description can be hard to interpret without that context.
The findings arrive as psychedelic compounds are being tested for mental health disorders. That research makes a more precise vocabulary for adverse effects and aftereffects increasingly valuable. Recognizing that PPAs can occur without distress may help researchers avoid collapsing a wide range of experiences into one category, while still identifying people who need support.
A research question, not a diagnostic shortcut
The study’s online-forum-heavy sample and its focus on self-reported experiences mean its results should be read as evidence about a recruited group, not as a population-wide prevalence estimate. The researchers’ contribution is to draw attention to a side effect that Greenwald said is more common than many people appreciate, and to examine its relationship to psychosis-risk measures.
For clinicians and researchers, the next task is to determine which characteristics matter most: the form of the perceptual change, whether it causes distress or impairment, when it occurs, and how it relates to other signs of risk. For people who have used psychedelics, the study reinforces that lingering visual changes can exist on a spectrum and that unusual perceptions alone do not settle the question of psychosis.
That nuance is especially important as psychedelic research expands. Better evidence about persistent aftereffects could improve both safety monitoring and clinical interpretation, allowing researchers to take unusual experiences seriously without treating every report as evidence of the same condition.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
